Abstract

BackgroundHIV-1 subtype D infections, which are associated with a faster rate of progression and lymphocyte CD4 decline, cognitive deficit and higher mortality, have rarely been found in native Europeans. In Northwestern Poland, however, infections with this subtype had been identified. This study aimed to analyze the sequence and clinical data for patients with subtype D using molecular phylogeography and identify transmission clusters and ancestry, as well as drug resistance, baseline HIV tropism and antiretroviral treatment efficacy.MethodsPhylogenetic analyses of local HIV-1 subtype D sequences were performed, with time to the most recent common ancestor inferred using Bayesian modeling. Sequence and drug resistance data were linked with the clinical and epidemiological information.ResultsSubtype D was found in 24 non-immigrant Caucasian, heterosexually infected patients (75% of females, median age at diagnosis of 49.5 years; IQR: 29–56 years). Partial pol sequences clustered monophyletically with the clades of Ugandan origin and no evidence of transmission from other European countries was found. Time to the most common recent ancestor was 1989.24 (95% HPD: 1968.83–1994.46). Baseline drug resistance to nucleoside reverse transcriptase inhibitors was observed in 54.5% of cases (mutations: M41L, K103N, T215S/D) with evidence of clustering, no baseline integrase or protease resistance and infrequent non-R5 tropism (13.6%). Virologic failure was observed in 60% of cases and was associated with poor adherence (p<0.001) and subsequent development of drug resistance (p = 0.008, OR: 20 (95%CI: 1.7–290).ConclusionsLocal subtype D represented an independently transmitted network with probably single index case, high frequency of primary drug resistance and evidence of transmission clusters.

Highlights

  • Phylogenetic analyses have been widely implemented in molecular epidemiology of HIV infection and allowed to understand genetic sequence variability, and to trace the flow of the variants and drug resistant clades as well as to infer a rate of molecular evolution to date the ancestry [1]

  • Tracking changes in HIV epidemics related to subtype diversity and drug resistance is important in Europe, where genetic diversity of HIV is rising, with a trend to increase the prevalence of non-subtype B infections [3]

  • We have previously identified higher prevalence of non-B subtypes, with a number of subtype D clades in the local population from Northwestern Poland (21%)

Read more

Summary

Introduction

Phylogenetic analyses have been widely implemented in molecular epidemiology of HIV infection and allowed to understand genetic sequence variability, and to trace the flow of the variants and drug resistant clades as well as to infer a rate of molecular evolution to date the ancestry [1]. Tracking changes in HIV epidemics related to subtype diversity and drug resistance is important in Europe, where genetic diversity of HIV is rising, with a trend to increase the prevalence of non-subtype B infections [3]. Onward infections with the non-subtype B clades reported in Europe were mostly acquired from the partners originating from countries of the higher HIV prevalence [8,9], unique epidemics among drug users have been noted [10]. Such explosive outbreaks in countries where drug injection is, or used to be common, were observed both for subtype B and non-B clades. This study aimed to analyze the sequence and clinical data for patients with subtype D using molecular phylogeography and identify transmission clusters and ancestry, as well as drug resistance, baseline HIV tropism and antiretroviral treatment efficacy

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.